|
|
|
|
|
Imiglucerase
drug data and news
Imiglucerase drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Imiglucerase | ||
| Brand Names/Synonyms | Glucosylceramidase precursor;Beta-glucocerebrosidase;Acid beta-glucosidase;D-glucosyl-N-acylsphingosine glucohydrolase;Alglucerase;Imiglucerase; Cerezyme (Genzyme Corp); Ceredase (Genzyme) | ||
| Indication | For treatment of Gaucher's disease (deficiency in glucocerebrosidase) | ||
| Sponsored links | Description | Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues | |
| Pharmacology | Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of imiglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside leading to reduced anemia and thrombocytopenia, reduced spleen and liver size, and decreased cachexia | ||
| Mechanism Of Action | Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids. | ||
| Imiglucerase News (When available) |
Genzyme Reports Financial Results for Fourth Quarter of 2005 and ... Feb 15, 2006 Genzyme Reports Financial Results for Fourth Quarter of 2005 and ... Feb 15, 2006 | ||
| Dosage Forms | POWDER FOR SOLUTION | ||
| Drug_Category | Enzyme replacement; enzymes (44:00.00) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Human Beta-glucocerebrosidase | ||
| Chemical Formula | C2532H3854N672O711S16 | ||
| Molecular Weight | 55597.4 | ||
| Smiles String | Not Available | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.168 | ||
| Isoelectric Point | 7.41 | ||
| Biotransformation | Not Available | ||
| Half Life | 3.6-10.4 min | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Imiglucerase.html http://www.rxlist.com/cgi/generic2/imiglucerase.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00026 | ||
| CAS Registry Number | 143003-46-7 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA449967 | ||
| SwissProt ID | GLCM_HUMAN (P04062) | ||
| GenBank ID | M16328 | ||
| Drug ID Number [DIN] | 2241751 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |